Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in Israel

Author:

Gilboa Mayan123,Gonen Tal1,Barda Noam1456,Cohn Shelly1,Indenbaum Victoria7,Weiss-Ottolenghi Yael1,Amit Sharon38,Asraf Keren9,Joseph Gili1,Levin Tal7,Kanaaneh Yara7,Aydenzon Alex7,Canetti Michal13,Freedman Laurence10,Zuckerman Neta7,Mendelson Ella37,Doolman Ram9,Kreiss Yitshak311,Regev-Yochay Gili123,Lustig Yaniv37

Affiliation:

1. The Sheba Pandemic Preparedness Research Institute, Sheba Medical Center, Ramat Gan, Israel

2. The Infection Prevention & Control Unit, Sheba Medical Center, Ramat Gan, Israel

3. Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel

4. ARC Innovation Center, Sheba Medical Center, Ramat Gan, Israel

5. Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be’er Sheva, Israel

6. Department of Epidemiology, Biostatistics and Community Health Sciences, Ben-Gurion University of the Negev, Be’er Sheva, Israel

7. Central Virology Laboratory, Public Health Directorate, Ministry of Health, Sheba Medical Center, Ramat Gan, Israel

8. Clinical Microbiology, Sheba Medical Center, Ramat Gan, Israel.

9. The Dworman Automated-Mega Laboratory, Sheba Medical Center, Ramat-Gan, Israel

10. Biostatistics and Biomathematics Unit, Gertner Institute of Epidemiology and Health Policy Research, Sheba Medical Center, Ramat-Gan, Israel

11. General Management, Sheba Medical Center, Ramat Gan, Israel

Abstract

ImportanceA correlation between antibody levels and risk of infection has been demonstrated for the wild-type, Alpha, and Delta SARS-COV-2 variants. High rates of breakthrough infections by the Omicron variant emphasized the need to investigate whether the humoral response elicited by mRNA vaccines is also associated with reduced risk of Omicron infection and disease.ObjectiveTo investigate whether the high antibody levels in individuals who have received at least 3 doses of an mRNA vaccine are associated with reduced risk of Omicron infection and disease.Design, Setting, and ParticipantsThis prospective cohort study used serial real time–polymerase chain reaction (RT-PCR) and serological test data from January and May 2022 to assess the association of preinfection immunoglobin G (IgG) and neutralizing antibody titers with incidence of Omicron variant infection, incidence of symptomatic disease, and infectivity. Participants included health care workers who had received 3 or 4 doses of an mRNA COVID-19 vaccine. Data were analyzed from May to August 2022.ExposuresLevels of SARS-CoV-2 anti–receptor binding domain IgG and neutralizing antibodies.Main Outcomes and MeasuresThe main outcomes were incidence of Omicron infection, incidence of symptomatic disease, and infectivity. Outcomes were measured using SARS-COV-2 PCR and antigen testing and daily online surveys regarding symptomatic disease.ResultsThis study included 3 cohorts for 3 different analyses: 2310 participants were included in the protection from infection analysis (4689 exposure events; median [IQR] age, 50 [40-60] years; 3590 [76.6%] among female health care workers), 667 participants (median [IQR] age, 46.28 (37.44,54.8); 516 [77.4%] female) in the symptomatic disease analysis, and 532 participants (median [IQR] age, 48 [39-56] years; 403 [75.8%] female) in the infectivity analysis. Lower odds of infection were observed for each 10-fold increase in preinfection IgG (odds ratio [OR], 0.71; 95% CI, 0.56-0.90) and for each 2-fold increase in neutralizing antibody titers (OR, 0.89; 95% CI, 0.83-0.95). The odds of substantial symptomatic disease were reduced for each 10-fold increase in IgG levels (OR, 0.48; 95% CI, 0.29-0.78) and for each 2-fold increase in neutralizing antibodies levels (OR, 0.86; 95% CI, 0.76-0.96). Infectivity, assessed by mean cycle threshold value, was not significantly decreased with increasing IgG or neutralizing antibodies titers.Conclusions and RelevanceIn this cohort study of vaccinated health care workers, IgG and neutralizing antibody titer levels were associated with protection against infection with the Omicron variant and against symptomatic disease.

Publisher

American Medical Association (AMA)

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3